LifeSci Capital downgraded Aeglea BioTherapeutics to Market Perform from Outperform and removed the firm’s price target after the company reported interim results from the Phase 1/2 study with pegtarviliase, or AGLE-177, for homocystinuria, or HCU. Aeglea announced that it is exploring strategic alternatives after the trial disappointed in the third treatment cohort, the firm noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AGLE:
- Aeglea BioTherapeutics price target removed at H.C. Wainwright
- Aeglea BioTherapeutics downgraded to Hold from Buy at JonesResearch
- Aeglea BioTherapeutics exploring strategic alternatives
- Aeglea BioTherapeutics announces interim Phase 1/2 results of pegtarviliase
- Aeglea BioTherapeutics reports Q4 revenue $200K, consensus $60K